Abstract
Haemorrhages represent a major complication of treatment with vitamin K antagonists. In cases of severe bleeding, a prompt effect on the increased International Normalized Ratio value is vital to achieve haemostasis. As conventional treatment, that is plasma or plasma-derived concentrates, carries the risk of blood-borne virus transmission, new treatments are needed. An open, multicentre pilot trial is currently under way to determine the effect of recombinant activated factor VII (rFVIIa; NovoSeven) administered to patients experiencing a bleeding episode after receiving vitamin K antagonists. When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate haemostatic effect and the International Normalized Ratio value virtually normalized.
| Original language | English |
|---|---|
| Pages (from-to) | S113-S115 |
| Journal | Blood Coagulation and Fibrinolysis |
| Volume | 11 |
| Issue number | Suppl 1 |
| Publication status | Published - 2000 |
Bibliographical note
The information about affiliations in this record was updated in December 2015.The record was previously connected to the following departments: Clinical Coagulation Research Unit (013242510), Emergency medicine/Medicine/Surgery (013240200)
Subject classification (UKÄ)
- Hematology